Ulcerative Colitis : A Literature Review

Authors

  • Ekawaty Retnaningsih Program Studi Pendidikan Dokter, Fakultas Kedokteran dan Ilmu Kesehatan Universitas Mataram
  • Sabila Izzatina Azmy Mujahid Program Studi Pendidikan Dokter, Fakultas Kedokteran dan Ilmu Kesehatan Universitas Mataram
  • Illiyani Sholihatin Program Studi Pendidikan Dokter, Fakultas Kedokteran dan Ilmu Kesehatan Universitas Mataram
  • Safira Said Hayaza Program Studi Pendidikan Dokter, Fakultas Kedokteran dan Ilmu Kesehatan Universitas Mataram
  • Ini Hidayat Makbul Program Studi Pendidikan Dokter, Fakultas Kedokteran dan Ilmu Kesehatan Universitas Mataram
  • Afif Farras Program Studi Pendidikan Dokter, Fakultas Kedokteran dan Ilmu Kesehatan Universitas Mataram
  • Mohammad Sany Rosafi Amanullah Program Studi Pendidikan Dokter, Fakultas Kedokteran dan Ilmu Kesehatan Universitas Mataram
  • Metta Octora Departemen Mikrobiologi Klinik, Fakultas Kedokteran dan Ilmu Kesehatan Universitas Mataram, Mataram, Indonesia.

DOI:

https://doi.org/10.29303/jk.v13i3.5045

Keywords:

Ulcerative colitis, Risk factors, Diagnosis, supporting, examinations, Management, Prognosis and Complications

Abstract

Ulcerative colitis (UC) is a chronic inflammatory bowel disease, with unknown etiology. Various risk factors, such as genetics, lifestyle, immunity and environment, are thought to contribute to the pathogenesis of UC. This disease has a high incidence in both developed and developing countries so it is a global concern. Ulcerative colitis sufferers experience mucosal inflammation that starts from the rectum and can spread to the proximal segment of the large intestine. Typical symptoms that appear are bloody diarrhea, abdominal pain, stool urgency, and tenesmus. The diagnosis of UC is made based on symptoms consistent with UC as well as endoscopic evidence showing persistent and spreading colonic inflammation starting in the rectum. There are several classes of drugs used to treat this disease. Mild to moderate UC uses oral and rectal 5-aminosalycilates. Meanwhile, moderate to severe UC with treatment classes includes thiopurines, biological agents that target tumor necrosis factor and integrins, and small molecule Janus kinase inhibitors.

Downloads

Published

2024-10-02

Issue

Vol. 13 No. 3 (2024): Jurnal Kedokteran

Section

Articles

License

Authors who publish with Unram Medical Journal, agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License (CC-BY License). This license allows authors to use all articles, data sets, graphics, and appendices in data mining applications, search engines, websites, blogs, and other platforms by providing an appropriate reference. The journal allows the author(s) to hold the copyright without restrictions and will retain publishing rights without restrictions.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in University of Mataram's Journal of Medicine. 
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
  4. This journal is open access journal which means that all content is freely available without charge to users or / institution. Users are allowed to read, download, copy, distribute, print, search, or link to full text articles in this journal without asking prior permission from the publisher or author.